小血管血管炎导致严重急性损伤后Ipilimumab:一个病例报告
Rui Duarte1, Filipa Trigo, Ivan Luz
1Nephrology Department, Centro Hospitalar do Médio Tejo, Torres Novas, Portugal.
Melanoma research
|November 28, 2023
概括
免疫检查点抑制剂,如 ipilimumab,可以导致罕见的脏问题. 一个独特的案例显示,在治疗黑色素瘤后,具有免疫沉积的小血管血管炎.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 免疫检查点抑制剂 (ICI) 是革命性的癌症疗法,特别是在转移性黑色素瘤.
- ICI通过向使癌细胞能够逃避免疫检测的蛋白质来起作用.
- 虽然有效,但ICI可以引发与免疫相关的不良事件 (irAEs),通常影响皮肤和胃肠道.
研究的目的:
- 报告ICI治疗后发生的罕见脏病例.
- 为了突出小血管血管炎的独特表现,与ipilimumab后的动脉性免疫沉积.
主要方法:
- 病例报告详细介绍了一名因转移性黑色素瘤而接受ipilimumab治疗的患者.
- 对临床表现,实验室发现和脏活检结果的审查.
- 对脏活检样本的组织病理学检查.
主要成果:
- 患者在接受伊皮利穆马布治疗后出现了脏并发症.
- 脏活检显示了小血管血管炎.
- 动脉免疫沉积是活检的一个关键发现.
结论:
- 脏参与,虽然很少见,但可以表现为小血管血管炎,在伊皮利姆巴治疗后免疫沉积.
- 这一案例扩大了已知的ICI诱导毒性的范围.
- 在接受ICI的患者中,对脏并发症的警至关重要.
相关概念视频
Acute Pyelonephritis I: Introduction
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...


